HPV Specific Testing: A Requirement for Oropharyngeal Squamous Cell Carcinoma Patients

被引：60

作者：

Max Robinson

Andrew Schache

Philip Sloan

Selvam Thavaraj

机构：

[1] Centre for Oral Health Research, School of Dental Sciences, Newcastle University, Newcastle upon Tyne NE2 4BW, Framlington Place

[2] Cellular Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne

[3] Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool

[4] Regional Maxillofacial Unit, University Hospital Aintree, Liverpool

[5] Oral Pathology, King's College London Dental Institute, London

来源：

Head and Neck Pathology | 2012年 / 6卷 / Suppl 1期

关键词：

Human papillomavirus; Molecular diagnosis; Oropharynx; Squamous cell carcinoma;

D O I：

10.1007/s12105-012-0370-7

中图分类号：

学科分类号：

摘要：

Human papillomavirus (HPV) testing is now recommended as part of the work up for patients with oropharyngeal squamous cell carcinoma (OPSCC) and those patients with cervical lymph node metastasis of unknown origin. The laboratory testing strategy should accurately assess the presence or absence of oncogenic HPV infection in routinely collected tumour samples that are subject to standard fixation protocols, alcohol-fixed cytological preparations and formalin-fixed tissue samples. The HPV status should correlate with biologically relevant outcome measures such as overall, disease-specific and disease-free survival. Whilst increased expression of p16 by immunohistochemistry is considered to be a surrogate marker of oncogenic HPV infection and is a validated independent prognostic biomarker, only HPV specific tests provide definitive evidence of the aetiological agent. We provide an overview of HPV testing in OPSCC, justifying the use of HPV specific tests. We examine the analytical accuracy of HPV specific tests against the 'reference' test-high risk HPV mRNA in fresh tissue-and contrast this with the performance of p16 immunohistochemistry as a stand alone test. We highlight the added value of HPV specific tests in prognostication, clinical trial design, and population-based disease surveillance. We consider that HPV specific testing is the starting point for developing increasingly informative biomarker panels in the context of 'stratified medicine'. We briefly frame test information in the context of disclosure of HPV status to patients. We conclude that only a testing strategy that includes HPV specific tests can deliver more effective care for patients with OPSCC. The international head and neck oncology community should work together to clearly define the minimum requirements for assigning a diagnosis of HPV-related OPSCC in order to ensure consistent reporting of this emerging and increasingly prevalent disease. © 2012 Springer Science+Business Media, LLC.

引用

页码：83 / 90

页数：7

共 25 条

[1]

Marur S., D'Souza G., Westra W.H., Forastiere A.A., HPV-associated head and neck cancer: a virus-related cancer epidemic, Lancet Oncol, 11, 8, pp. 781-789, (2010)

[2]

Braakhuis B.J., Brakenhoff R.H., Meijer C.J., Snijders P.J., Leemans C.R., Human papilloma virus in head and neck cancer: the need for a standardised assay to assess the full clinical importance, Eur J Cancer, 45, 17, pp. 2935-2939, (2009)

[3]

Leemans C.R., Braakhuis B.J., Brakenhoff R.H., The molecular biology of head and neck cancer, Nat Rev Cancer, 11, 1, pp. 9-22, (2011)

[4]

van Houten V.M., Snijders P.J., van den Brekel M.W., Kummer J.A., Meijer C.J., van Leeuwen B., Et al., Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas, Int J Cancer, 93, 2, pp. 232-235, (2001)

[5]

Wiest T., Schwarz E., Enders C., Flechtenmacher C., Bosch F.X., Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control, Oncogene, 21, 10, pp. 1510-1517, (2002)

[6]

Smeets S.J., Hesselink A.T., Speel E.J., Haesevoets A., Snijders P.J., Pawlita M., Et al., A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen, Int J Cancer, 121, 11, pp. 2465-2472, (2007)

[7]

Schache A.G., Liloglou T., Risk J.M., Filia A., Jones T.M., Sheard J., Et al., Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination, Clin Cancer Res, 17, 19, pp. 6262-6271, (2011)

[8]

Shi W., Kato H., Perez-Ordonez B., Pintilie M., Huang S., Hui A., Et al., Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma, J Clin Oncol, 27, 36, pp. 6213-6221, (2009)

[9]

Perrone F., Gloghini A., Cortelazzi B., Bossi P., Licitra L., Pilotti S., Isolating p16-positive/HPV-negative oropharyngeal cancer: an effort worth making, Am J Surg Pathol., 35, 5, pp. 774-777, (2011)

[10]

Singhi A.D., Westra W.H., Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience, Cancer, 116, 9, pp. 2166-2173, (2010)

← 1 2 3 →